Advertisement Covers CROI 2017


Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

April 2017

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data from IMPAACT P1110 presented at CROI 2017.

Previous studies have shown raltegravir (RAL) elimination to be highly variable in the first weeks of life due to low UGT1A1 activity.

IMPAACT P1110 is a phase I multicentre study in full-term HIV-1 exposed neonates at high risk of HIV with or without maternal RAL exposure. It includes two cohorts: cohort 1 infants received two single RAL doses one week apart; cohort 2 infants received daily RAL dosing for first six weeks of life.

The study sites are in Brazil, South Africa and the US.

PK data from cohort 1 and from older infants and children in IMPAACT P1066 were combined in a population PK model. The model included maturation of absorption rate from 16% of max at birth to 90% at two weeks, and clearance from close to nil to max at approximately six months of age.

The model was used to perform simulations of possible daily dosing regimens for RAL-naive infants in cohort 2 (using oral granules for suspension). See Table 1.

Table 1: Raltegravir Dosing in IMPAACT P1110
Days of Life Dose mg/kg Frequency
1-7 1.5 Once daily
8-28 3.0 Twice daily
after 28 6.0 Twice daily

Plasma samples were collected at the following time points. First dose: pre-dose, 1-2, 6-10 and 20-24 hours post dose. Second dose: 3-6 hours post dose. Day 6-9 of life: pre-dose. Day 15-18 of life: pre-dose, 4-6 and 8-12 hours post-dose. Day 28-32 of life: pre-dose. Week 5-6 of life: pre-dose and 3-6 hours post-dose.

Exposure targets are: AUC24 12-40 mg*h/L; AUC12 6-20 mg*h/L; C12 or C24 > 33 ng/mL; and Cmax <8724 ng/mL.

Cohort 2 enrolled 26 infants: 46% female; 69% black, 12% white and 19% other; median gestation age 38.5 weeks and birth weight 2.93 kg. Evaluable PK and 6-week safety data were available for 25 infants.

The investigators reported no drug related adverse events. All RAL exposure targets were met; PK parameters are shown in Table 2.

Table 2: Raltegravir PK Parameters IMPAACT 1110
After Initial Dose: 1.5 mg/kg Once Daily (n=25) Day 15-18: 3.0 mg/kg Twice Daily (n=24)
Geometric mean (CV) Target Geometric mean (CV) Target
AUC (mg*h/L) 38.2 (38.4%) 11 above 13 met 0 below 14.3 (43.3%) 8 above 14 met 1 below
Trough (ng/mL) 948 (64.2%) 25 above 0 below 176 (93.8%) 22 above 1 below
Cmax (mg/mL) 2350 (35.0%) 0 above 25 below 2850


0 above 24 below
Tmax (mg/mL) 5.4 (57.5%) 5.4 (57.5%)
T1/2 (hours) 15.8 (174.8%) 15.8 (174.8%)

The investigators noted that after the initial dose some infants had AUC24 slightly above target range -- but they considered this to be acceptable given the rapid increase in RAL metabolism over the first week of life.

Infants born to mothers who received RAL and low birth weight infants are to be studied in IMPAACT P1110.


Clarke DF et al. Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: dose-finding study. CROI 2017.13-17 February 2017. Seattle. Poster abstract 757. (abstract and poster)

Related Stories

Raltegravir in HIV-Exposed Neonates
Raltegravir-Based Third-Line ART in Children and Adolescents

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.